Novo research director on obesity study: "We couldn't have hoped for a better start"

The first phase III study of Novo Nordisk's drug semaglutid in obesity exceeded the company's expectations and, according to research director Mads Krogsgaard Thomsen, proves that obesity is a chronic illness which needs to be treated like diabetes or high blood pressure.

Mads Krogsgaard Thomsen, research director at Novo Nordisk Photo: Jacob Ehrbahn / Ritzau Scanpix

Log in to read our articles

Welcome to MedWatch. A part of our content is exclusive and reserved for our users.

Try MedWatch for 14 days.

Get a trial subscription here.

Do you want a trial subscription with multiple users for yourself and your colleagues?

Read more about your options and find the contact information to our sales team here.

Related articles